We hope to optimize the structure of this carfentanil amide scaffold to maintain receptor affinities and MOR agonism, while reducing the DOR efficacy to attain a MOR agonist/DOR antagonist based pharmacophore to address respiratory depression, which was observed with the current lead molecule. This evidence concerns the gene OPRM1 and Respiratory insufficiency due to muscle weakness.